Get the Stockscreener App
13.15
0.15%
0.02
After Hours:
12.85
-0.30
-2.28%
Celcuity Inc stock is traded at $13.15, with a volume of 312.55K.
It is up +0.15% in the last 24 hours and up +17.31% over the past month.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
See More
Previous Close:
$13.13
Open:
$13.28
24h Volume:
312.55K
Relative Volume:
1.19
Market Cap:
$488.25M
Revenue:
-
Net Income/Loss:
$-63.78M
P/E Ratio:
-4.9067
EPS:
-2.68
Net Cash Flow:
$-53.91M
1W Performance:
+2.10%
1M Performance:
+17.31%
6M Performance:
-22.60%
1Y Performance:
-8.36%
1-Day Range:
$12.97
$13.43
1-Week Range:
$12.55
$13.43
52-Week Range:
$10.35
$22.19
Celcuity Inc Stock (CELC) Company Profile
Name
Celcuity Inc
Sector
Industry
Phone
763-392-0767
Address
16305 36TH AVENUE N, MINNEAPOLIS, MN
Compare CELC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELC
Celcuity Inc
|
13.15 | 488.25M | 0 | -63.78M | -53.91M | -2.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Celcuity Inc Stock (CELC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Feb-22-24 | Initiated | Stifel | Buy |
| Dec-08-23 | Initiated | H.C. Wainwright | Buy |
| Oct-08-21 | Initiated | Canaccord Genuity | Buy |
| Sep-07-21 | Initiated | Jefferies | Buy |
| Jul-29-21 | Initiated | Cowen | Outperform |
| Jul-27-21 | Initiated | Needham | Buy |
| Jan-28-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-24-20 | Reiterated | H.C. Wainwright | Buy |
| May-11-20 | Resumed | Craig Hallum | Buy |
| Nov-20-18 | Initiated | H.C. Wainwright | Buy |
View All
Celcuity Inc Stock (CELC) Latest News
Celcuity Inc. (NASDAQ:CELC) Short Interest Up 6.4% in January - MarketBeat
Celcuity Set to Join Russell 2000 and 3000 Indexes - ACCESS Newswire
Celcuity’s High-Stakes Oncology Bet Is Underappreciated (NASDAQ:CELC) - Seeking Alpha
Q1 Earnings Forecast for Celcuity Issued By Leerink Partnrs - MarketBeat
Bleakley Financial Group LLC Acquires Shares of 11,159 Celcuity Inc. (NASDAQ:CELC) - Defense World
Q2 Earnings Estimate for Celcuity Issued By Leerink Partnrs - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Given Average Rating of "Buy" by Analysts - MarketBeat
Needham & Company LLC Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price - MarketBeat
Q1 Earnings Estimate for Celcuity Issued By Leerink Partnrs - Defense World
Celcuity Inc. (NASDAQ:CELC) Receives $30.17 Consensus Price Target from Brokerages - Defense World
Scorpion stinger bringer of more PI3Kα inhibitor deals? - BioWorld Online
BlackRock, Inc. Expands Holdings with Celcuity Inc. Acquisition - GuruFocus.com
(CELC) Technical Data - Stock Traders Daily
JPMorgan Chase & Co. Sells 11,612 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference - ACCESS Newswire
Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates - ACCESS Newswire
Celcuity Announces FDA Breakthrough Therapy Designation for Gedatolisib for Treatment of HR+/HER2- Metastatic Breast Cancer - ACCESS Newswire
When (CELC) Moves Investors should Listen - Stock Traders Daily
Jefferies lifts Celcuity stock target to $33, maintains Buy rating - MSN
Jefferies lifts Celcuity stock target to $33, maintains Buy rating By Investing.com - Investing.com Australia
Celcuity Closes $100 Million Private Placement - ACCESS Newswire
Celcuity Inc. Announces $50 Million Private Placement - ACCESS Newswire
Hennion & Walsh Asset Management Inc. Buys 71,006 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Average PT from Analysts - Defense World
Celcuity Inc. (NASDAQ:CELC) Holdings Raised by Barclays PLC - Defense World
Celcuity Inc. (NASDAQ:CELC) Shares Bought by Barclays PLC - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Receives $29.17 Average PT from Brokerages - MarketBeat
Analyzing Celcuity (NASDAQ:CELC) and CannLabs (OTCMKTS:CANL) - Defense World
Jane Street Group LLC Sells 9,921 Shares of Celcuity Inc. (NASDAQ:CELC) - Defense World
Celcuity stock touches 52-week low at $11.51 amid market challenges - Investing.com Australia
Objective long/short (CELC) Report - Stock Traders Daily
Geode Capital Management LLC Acquires 136,518 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity Inc. (NASDAQ:CELC) Shares Purchased by Geode Capital Management LLC - Defense World
Celcuity Inc. (NASDAQ:CELC) Shares Acquired by Barclays PLC - Defense World
Barclays PLC Raises Stock Position in Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity (NASDAQ:CELC) Trading Up 3.8%Here's Why - MarketBeat
State Street Corp Purchases 668,318 Shares of Celcuity Inc. (NASDAQ:CELC) - MarketBeat
Celcuity Inc Stock (CELC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):